Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what data her Department holds on the number of individuals convicted of fraud related to contracts with her Department for the provision of personal protective equipment in the last four years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
To date, no individuals have been convicted of fraud related to personal protective equipment contracts. Work continues to recover costs wherever possible to ensure taxpayer value for money.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding his Department has provided to the West Midlands Ambulance Service Student's Paramedic Apprenticeship Programme in the latest period for which data is available.
Answered by Will Quince
The Department does not provide levy funding for apprenticeships. HM Revenue & Customs collect Apprenticeship Levy payments and funding is allocated and drawn down by employers via the Department for Education.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many prescriptions for (a) Nabilone, (b) Savitex and (c) unlicensed cannabis-based products for medicinal use were issued by private healthcare specialist prescribers and dispensed in the community in October 2019.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.
The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.
In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.
Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.
Note:
*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many prescriptions for unlicensed cannabis-based products for medicinal use were prescribed by the NHS and dispensed in the community in October 2019.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.
The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.
In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.
Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.
Note:
*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many prescriptions for (a) Nabilone Savitex, (b) Epidiolex and (c) unlicensed cannabis-based products for medicinal use were dispensed by hospital pharmacies from November 2018 to October 2019.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.
The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.
In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.
Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.
Note:
*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the average cost to the NHS was of prescriptions for unlicensed cannabis-based products for medicinal use from November 2018 to October 2019.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.
The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.
In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.
Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.
Note:
*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what provision the Government has in place to provide extra funding for clinical commissioning groups to deal with increasing local pressures on social care resulting from limits on local authority resources and NHS trusts being placed on special measures.
Answered by Alistair Burt
The Better Care Fund gives flexibility to local areas to determine how best to invest a joint budget. Local authorities are required to agree with their local health partners how funding is best used within social care in order to best serve local people and reduce pressures on the health service.
The total value of the Better Care Fund in 2015/16 is £5.3 billion, which includes monies provided by local authorities and health partners in 151 local areas.
From April 2017, the Spending Review makes available additional social care funds for local government, rising to £1.5 billion by 2019/20, to be included in the Better Care Fund.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps the Government is taking to help pressures on local health care services resulting from an increasing population of elderly people.
Answered by Alistair Burt
We know there are challenges ahead across the health and care sectors, but the principle with which we will approach the decisions ahead will be to prioritise and maximise funding for frontline services. The Government believes that the answer to these challenges lies in changing the way services are delivered and keeping people well and independent for longer, not in altering the fundamental principles that underpin the National Health Service.
As a result of the Spending Review, NHS funding will be £10 billion higher in real terms by 2020-21 than 2014-15. And the NHS will not have to wait until the end of the parliament for much of this investment. We will be giving the NHS £3.8 billion more next year, over and above inflation, and almost £6 billion of the £10 billion in the first two years of the six year period. This shows that the Government has listened and responded to what the NHS has said about the level of investment it needs to deliver the Five Year Forward View.
The Five Year Forward View – the NHS’s own plan – takes account of rising demand from demographic change and sets out new models of care that can meet the changing needs of patients, including better meeting the needs of the frail elderly, and maximising the opportunities presented by new technologies and treatments. The aim of the new care models programme is to secure the future of the NHS for all of us to continue receiving high quality care, when and where we need it.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how many finished admission episodes were carried out between May 2010 and the latest period for which figures are available; and how many such procedures were carried out in the equivalent period in the previous Parliament.
Answered by Jane Ellison
In the first four years of this Parliament, between 1 May 2010 and 31 March 2014, which is the latest period for which data is available, there were around 59 million finished admission episodes.
During the first four years of the previous Parliament (between 1 May 2005 and 31 March 2009), there were around 52 million finished admission episodes.
Asked by: Mark Garnier (Conservative - Wyre Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with reference to paragraph 132 of the judgment of the European Court of Justice in the case C-491/01 - British American Tobacco (Investments) and Imperial Tobacco, 10 December 2002, if he will ensure that legislative proposals he plans to bring forward on the standardised packaging of tobacco will meet the standard set down in that judgment for sufficient space to be provided on that packaging to affix other material, in particular concerning trademarks.
Answered by Jane Ellison
In coming to its decision to proceed with the Standardised Packaging of Tobacco Regulations, the Government has given careful consideration to all the legal issues, including the implications of relevant European case law.